A significant debate is unfolding within China’s medical community as the nation accelerates its artificial intelligence integration in healthcare. Dr. Zhang Wenhong, a renowned infectious disease expert from Fudan University who gained national prominence during the COVID-19 pandemic, has publicly expressed reservations about incorporating AI into critical medical systems.
At a Hong Kong forum on January 10, Dr. Zhang stated his firm opposition to implementing AI in hospital medical record systems, emphasizing concerns about how machine-generated outputs might compromise clinical judgment. While acknowledging AI’s potential utility, the prominent physician insisted that human expertise must remain central to medical practice. “I can tell where AI is wrong,” Zhang asserted. “I won’t be misled by it.”
The expert’s primary concern centers on medical education and training. He warned that if AI-generated conclusions become default “standard answers” in diagnosis and treatment, young physicians might never develop essential critical evaluation skills. “Without systematic training, doctors will lose the ability to judge whether AI’s conclusions are correct,” Zhang explained, advocating that future physicians must master assessing AI reliability and managing complex cases beyond algorithmic capabilities.
Despite these concerns, AI adoption continues to expand across Chinese hospitals. At Ningbo University’s Affiliated People’s Hospital, an oncology tool called PANDA analyzes CT scans to identify pancreatic cancer risks, having already reviewed over 180,000 scans and detected more than 20 initially overlooked cancer cases. According to Dr. Zhu Kelei, director of hepatobiliary and pancreatic surgery, “AI entirely saved their lives in these cases.”
Primary-level hospitals with physician shortages are particularly enthusiastic about AI assistance. At Beijing’s Chuiyangliu Hospital affiliated with Tsinghua University, the Agent Hospital system is undergoing testing to help doctors track medical histories, locate treatments, and receive clinical suggestions more efficiently.
The global AI healthcare market, valued under $30 billion in 2024, is projected to reach $500 billion by 2033. In China, central and local governments are rolling out “AI+” initiatives, with over 100 medical device projects currently underway nationwide. Implementation typically begins in departments with standardized data, high workloads, and relatively low risks, with medical imaging, electrocardiography, and laboratory testing identified as priority areas.
However, skepticism persists within the medical establishment. Dr. Gao Wen of Capital Medical University noted, “Not every medical problem requires AI. Some technologies appear advanced but offer limited real benefit to healthcare.” As AI systems penetrate deeper into diagnosis and treatment, regulatory challenges are becoming increasingly difficult to ignore, highlighting the ongoing tension between technological advancement and medical tradition.